Zolacabtagene Autoleucel

Preferred Label : Zolacabtagene Autoleucel;

NCIt synonyms : Autologous CD19-targeted CAR T-cells CC-97540; Autologous CD19-targeted NEX-T CAR T Cells CC-97540; Autologous CD19-targeted CAR T Cells CC-97540;

NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, zolacabtagene autoleucel specifically target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.;

UNII : DU963TX85S;

Molecule name : CC 97540; CC-97540;

NCI Metathesaurus CUI : CL1412307;

Détails

Origin ID

C175049;

UMLS CUI

C5418107;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients